Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?Philippe Aftimos; Ahmad Awada · 2011

1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN)Patsouris, A.; Septans, A.L.; Paillard, M.J.; Pivot, X.; Soibinet, P.; Jovenin, N.; Robert, M.; Gourmelon, C.; Korembaum, C.; Petit, T.; Martin-babau, J.; Brunot, A.; Lefeuvre-plesse, C.; Adele, M.; Bourgeois, H.; Som, M.; Uwer, L.; Campone, M.; Campion, L.; Tredan, O. · European Journal of Cancer · 2015

Future of oncologic photodynamic therapyAllison, Ron R; Bagnato, Vanderlei S; Sibata, Claudio H · Future Oncology · 2010

Epigenetic mechanisms in oral carcinogenesisGasche, Jacqueline A; Goel, Ajay · Future Oncology · 2012

The global breast cancer burdenBenson, John R; Jatoi, Ismail · Future Oncology · 2012

PTEN and melanomagenesisConde-Perez, Alejandro; Larue, Lionel · Future Oncology · 2012

Management of gastrointestinal stromal tumorsRajendra, Rajeev; Pollack, Seth M; Jones, Robin L · Future Oncology · 2013

Brivanib: a review of developmentChou, Tina; Finn, Richard S · Future Oncology · 2012

Tumor cohesion and glioblastoma cell dispersalFoty, Ramsey A · Future Oncology · 2013

Metformin, insulin, breast cancer and more…Berstein, Lev M · Future Oncology · 2009